backgroundkaposi
sarcomaassoci
herpesviru
kshv
associ
sever
malign
diseas
includ
kaposi
sarcoma
primari
effus
lymphoma
pel
multicentr
castleman
diseas
object
studi
explor
peptideconjug
phosphorodiamid
morpholino
oligom
ppmo
kshv
earli
lytic
gene
assess
efficaci
scid
mice
pel
engraft
ppmo
short
singlestrand
dna
analog
contain
backbon
morpholin
ring
phosphorodiamid
linkag
high
deliveri
effici
cell
methodspel
cell
treat
ppmo
viral
interferon
regulatori
factor
express
analyz
ppmo
viral
interleukin
evalu
pel
cell
engraft
scid
mice
ppmo
administ
periton
caviti
scid
mice
ten
dose
twoday
interv
week
deliveri
periton
lavag
collect
ratio
pel
cell
among
total
cell
determin
flow
cytometri
analysi
kaposi
sarcomaassoci
herpesviru
kshv
also
known
human
herpesviru
associ
sever
malign
diseas
includ
kaposi
sarcoma
ks
primari
effus
lymphoma
pel
multicentr
castleman
diseas
mcd
despit
use
highli
activ
antiretrovir
therapi
haart
reduc
incid
ks
diseas
remain
common
malign
patient
aid
develop
countri
current
antiherpesviru
drug
ganciclovir
cidofovir
foscarnet
target
dna
polymeras
express
late
lytic
phase
kshv
replic
limit
benefit
either
ks
pel
specif
antikshv
drug
still
muchneed
treatment
kshvassoci
malign
studi
peptideconjug
phosphorodiamid
morpholino
oligom
ppmo
explor
inhibit
express
kshv
earli
lytic
gene
suppress
engraft
pel
cell
mice
nonobes
diabeticsever
combin
immunodefici
diseas
nodscid
ppmo
short
singlestrand
dna
analog
contain
backbon
morpholin
ring
phosphorodiamid
linkag
ppmo
bind
complementari
target
mrna
watsoncrick
base
pair
block
translat
steric
blockad
distinctli
differ
process
rnase
hdepend
mechan
induc
antisens
structur
type
phosphorothio
dna
sequencespecif
antivir
efficaci
ppmo
document
number
rna
virus
anim
model
includ
ebola
viru
coxsackieviru
murin
coronaviru
dengu
viru
west
nile
viru
kshv
larg
doublestrand
dna
viru
encod
gene
like
herpesvirus
kshv
display
tightli
regul
program
gene
express
use
two
mode
infect
latent
lytic
reactiv
kshv
lytic
replic
pel
cell
induc
chemic
tetradecanoyl
phorbol
acet
tpa
lytic
replic
divid
immediateearli
earli
late
stage
base
express
time
viral
gene
activ
lytic
cycl
two
kshv
earli
lytic
gene
viral
interferon
regulatori
factor
viral
interleukin
among
implic
pathogenesi
kshvassoci
malign
diseas
encod
homolog
member
cellular
interferon
regulatori
factor
famili
interact
protein
inhibit
type
iii
human
interferon
ifn
signal
lead
transform
cell
well
induct
tumor
nude
mice
irf
famili
member
transcript
regulatori
factor
bind
interferonstimul
respons
element
isr
regul
interferonrespons
gene
involv
pathogen
respons
cytokin
signal
cell
growth
regul
hematopoiet
develop
protein
directli
interact
dna
bind
protein
interfer
function
inhibit
signal
transduct
pathway
downregul
total
protein
level
result
suggest
oncogen
protein
potenti
contribut
kshvdriven
malign
encod
express
cell
ks
lesion
greater
number
cell
pel
mcd
lesion
indic
role
kshvassoci
lymphoprolif
disord
homolog
human
import
autocrineparacrin
growth
factor
notabl
express
high
level
lymphoma
stimul
known
signal
pathway
treatment
cell
ppmo
lead
inhibit
express
result
slower
cell
growth
thu
multifunct
cytokin
potenti
contribut
kshvassoci
lymphoprolif
disord
consid
import
role
select
target
develop
antikshv
ppmo
ppmo
test
cell
cultur
pel
cell
nodscid
mice
engraft
cell
cell
deriv
primari
effus
lymphoma
patient
success
engraft
scid
mice
studi
found
two
ppmo
effect
inhibit
express
pel
cell
shown
western
blot
analysi
nodscid
mice
administr
ppmo
effect
block
engraft
cell
kshvinfect
nih
aid
research
refer
reagent
program
atcc
cell
deriv
bodi
cavitybas
lymphoma
cell
line
maintain
rpmi
medium
supplement
fetal
bovin
serum
induct
kshv
lytic
replic
tpa
sigma
st
loui
mo
ad
cell
growth
medium
final
concentr
ngml
ppmo
design
complementari
termin
region
mrna
sequenc
sequenc
ppmo
use
studi
gcctgggtccattgtcccgc
underlin
nucleotid
correspond
translat
initi
codon
aug
mrna
tagccgcagaattgcctgggt
complementari
nucleotid
complement
nucleotid
mrna
sequenc
genbank
access
number
ppmo
produc
avi
biopharma
inc
corval
conjug
argininerich
peptid
previous
describ
scrambl
ppmo
hereinaft
name
littl
agreement
kshv
human
mrna
sequenc
use
neg
control
ppmo
describ
previous
treatment
kshvinfect
cell
conduct
report
previous
briefli
cell
pellet
resuspend
rpmi
medium
plate
cell
cultur
plate
ppmo
immedi
ad
mix
incub
h
growth
medium
ad
final
volum
ml
per
well
cell
induc
tpa
medium
supplement
tpa
ngml
cell
incub
h
cell
cultur
supernat
harvest
analysi
express
kshv
protein
kshvinfect
cell
detect
western
blot
analysi
describ
previous
rabbit
antibodi
gift
dr
margaret
k
offermann
emori
univers
atlanta
georgia
goat
antirabbit
igg
conjug
horseradish
peroxidas
sigma
chemiluminesc
substrat
use
assay
chemiluminesc
signal
collect
chemidoc
xr
digit
imag
system
biorad
laboratori
hercul
ca
normal
also
detect
blot
membran
strip
similarli
western
blot
analysi
conduct
rabbit
rabbit
antibodi
santa
cruz
biotechnolog
inc
santa
cruz
ca
digit
imag
analys
conduct
use
quantiti
one
softwar
version
biorad
cell
viabil
assayth
viabil
cell
ppmoor
mocktreat
determin
celltiterglo
luminesc
cell
viabil
assay
promega
madison
wi
describ
previous
briefli
cell
treat
describ
tpa
use
assay
normal
cell
includ
comparison
h
ppmo
treatment
celltiterglo
reagent
ad
cell
accord
manufactur
instruct
luminesc
signal
detect
multilabel
counter
perkinelm
life
analyt
scienc
wellesley
genom
dna
cell
cultur
supernat
isol
use
dnazol
invitrogen
carlsbad
ca
realtim
pcr
conduct
chromo
detector
system
iq
sybr
green
supermix
biorad
describ
previous
primer
use
detect
kshv
dna
plasmid
use
gener
standard
curv
quantif
kshv
dna
copi
cultur
supernat
sixweekold
nodscid
femal
mice
purchas
anim
product
program
nci
frederick
md
mice
hous
microisol
cage
cage
food
water
bed
autoclav
prior
use
anim
experi
protocol
approv
institut
anim
care
use
committe
univers
maryland
mice
monitor
clinic
sign
ascit
develop
euthan
human
endpoint
reach
accord
protocol
cell
deliv
nodscid
mice
via
intraperiton
ip
rout
dose
cell
per
mous
describ
previous
periton
lavag
mice
collect
use
ml
serumfre
rpmi
week
postinocul
cell
vivo
propag
scid
mice
use
ppmo
studi
mice
ppmo
studi
mice
use
group
mice
group
receiv
million
cell
via
ip
inject
group
receiv
ppmo
treatment
group
receiv
treatment
respect
group
use
control
receiv
cell
ppmo
group
given
ppmo
treatment
cell
treat
ppmo
final
concentr
h
inject
scid
mice
via
ip
pb
use
mock
treatment
neg
control
group
mice
inject
ppmo
time
twoday
interv
dose
mgkg
volum
per
mous
mice
observ
daili
subject
periton
lavag
collect
week
inject
assess
tumor
cell
burden
fraction
lavag
sampl
cell
stain
phycoerythrin
pe
conjug
monoclon
antibodi
human
leukocyt
common
antigen
fitcconjug
antibodi
murin
bd
bioscienc
pharmingen
describ
previous
flow
cytometri
analysi
conduct
determin
ratio
total
number
cell
lavag
sampl
singl
factor
anova
statist
analysi
use
analyz
statist
differ
treatment
group
twotail
p
valu
less
consid
signific
differ
untransl
region
utr
mrna
nt
long
intern
ribosom
entri
site
region
around
translat
initi
codon
transcript
initi
select
target
ppmo
design
complementari
region
first
design
test
effect
inhibit
express
later
anoth
ppmo
design
confirm
sequencespecif
inhibit
complementari
mrna
also
import
region
ribosom
bind
scan
translat
mrna
scrambl
ppmo
contain
random
sequenc
includ
neg
control
ppmo
check
ncbi
blast
search
make
sure
potenti
target
cellular
gene
test
effect
target
gene
express
clone
utr
mrna
upstream
gfp
gene
vector
order
express
virfgfp
fusion
protein
result
plasmid
transient
transfect
cell
treatment
cell
conduct
h
transfect
includ
control
h
posttransfect
cell
observ
fluoresc
microscopi
comparison
cell
cell
much
fewer
cell
green
fluoresc
figur
indic
suppress
translat
target
virfgfp
transcript
cell
gfpposit
cell
similar
percentag
mocktreat
cell
result
indic
inhibit
virfgfp
fusion
protein
express
sequencespecif
test
ppmo
kshvinfect
pel
cell
immunofluoresc
assay
initi
conduct
rabbit
antibodi
detect
cell
tpa
induct
approxim
cell
express
expect
fewer
cell
treat
assess
level
total
protein
separ
sdspage
detect
western
blot
analysi
rabbit
antibodi
result
show
treatment
led
reduct
level
cell
figur
densitometri
analysi
digit
blot
imag
show
treatment
cell
reduc
level
comparison
mocktreat
cell
tpa
induct
figur
cell
treat
neglig
effect
protein
level
result
suggest
inhibit
express
cell
ppmo
also
test
anoth
cell
line
pel
make
sure
inhibit
cell
linespecif
cell
treat
harvest
h
posttreat
western
blot
analysi
show
treatment
reduc
level
cell
figur
effect
comparison
mocktreat
control
ppmo
complement
site
nt
upstream
complementari
site
mrna
treatment
cell
also
reduc
level
comparison
mocktreat
control
figur
inhibitori
effect
similar
effect
confirm
ppmomedi
inhibit
sequencespecif
indic
utr
mrna
product
region
ppmo
target
test
doserespons
effect
ppmo
treatment
inhibit
express
cell
use
similar
effect
along
increment
concentr
level
tpainduc
cell
decreas
dosedepend
manner
figur
contrast
treatment
much
effect
express
tpainduc
cell
cell
cultur
supernat
also
harvest
dna
isol
realtim
pcr
measur
kshv
dna
level
tpa
induct
led
elev
kshv
viral
dna
level
averag
kshv
dna
supernat
cell
significantli
reduc
comparison
control
supplement
figur
result
suggest
treatment
result
reduct
kshv
replic
tpainduc
cell
conduct
cell
viabil
assay
make
sure
ppmo
toxic
pel
cell
concentr
use
cell
viabil
assay
detect
signific
chang
cell
number
cell
treatment
rel
percentag
cell
viabil
cell
treat
comparison
nontreat
cell
supplement
figur
result
indic
ppmo
toxic
pel
cell
concentr
use
sinc
interact
cellular
interferon
regulatori
factor
specul
suppress
would
effect
express
sinc
similar
effect
express
use
experi
test
protein
level
cell
treat
mocktreat
cell
also
includ
comparison
interest
note
tpa
induct
led
reduct
level
figur
cell
treat
higher
level
treatment
result
suggest
treatment
suppress
express
reliev
inhibit
express
interferon
signal
pathway
import
transcript
factor
need
activ
express
ifnrespons
gene
specul
suppress
would
impact
cell
treat
level
higher
cell
treat
figur
band
intens
lane
lane
indic
suppress
cell
led
increas
express
cell
induc
tpa
express
level
much
alter
tpa
induct
scid
mous
model
pel
engraft
use
assess
efficaci
ppmo
vivo
cell
propag
intraperiton
caviti
scid
mice
use
experi
cell
propag
vivo
inocul
scid
mice
ascit
tumor
develop
much
quicker
mice
inocul
cell
cultur
vitro
sinc
effect
inhibit
express
cell
cultur
target
mrna
combin
one
group
mous
experi
effect
inhibit
ppmo
kshv
also
test
sinc
shown
effect
inhibit
express
result
reduct
cell
growth
cultur
scrambl
ppmo
includ
neg
control
five
mice
use
group
cell
incub
ppmo
h
inject
periton
caviti
mice
ppmo
administ
time
twoday
interv
week
inject
cell
periton
lavag
collect
cell
stain
determin
ratio
pel
cell
lavag
mice
treat
signific
averag
lower
ratio
pel
cell
less
total
cell
figur
background
level
neglig
two
mice
group
low
ratio
pel
cell
respect
tabl
though
averag
ratio
pel
cell
group
similar
treat
scrambl
ppmo
untreat
control
five
mice
group
low
ratio
less
pel
cell
mice
treat
mocktreat
group
rel
high
ratio
cell
indic
effici
engraft
pel
cell
week
inject
cell
periton
lavag
collect
mice
group
neglig
ratio
less
pel
cell
figur
tabl
healthi
averag
ratio
cell
lavag
neg
control
group
respect
one
mous
group
neglig
ratio
cell
periton
lavag
tabl
mice
high
ratio
cell
week
still
similar
higher
ratio
cell
week
mice
control
group
receiv
cell
euthan
day
human
endpoint
reach
tabl
mice
group
still
healthi
studi
end
day
cell
inject
ascit
develop
notic
mice
group
result
suggest
suppress
engraft
mice
surviv
time
mice
group
much
longer
other
figur
tabl
remain
healthi
end
studi
day
deliveri
cell
one
mous
group
mice
die
euthan
day
one
mous
group
neglig
ratio
cell
week
die
accid
handl
day
data
indic
inhibit
engraft
scid
mice
studi
explor
use
ppmo
earli
lytic
gene
demonstr
ppmo
inhibit
express
two
kshvinfect
pel
cell
line
ppmo
protect
scid
mice
pel
engraft
design
test
two
ppmo
complementari
translat
initi
region
mrna
ppmo
work
effici
inhibit
express
cell
indic
critic
translat
find
consist
previou
public
inhibit
antisens
ribozym
kshv
replic
also
reduc
pel
cell
specul
reduct
kshv
lytic
replic
might
result
allevi
inhibit
cellular
ifn
signal
pathway
data
elev
cell
also
support
specul
cell
inhibit
higher
level
play
import
role
ifnsign
antivir
respons
elev
cellular
gene
ifn
signal
pathway
encourag
data
explor
ppmo
potenti
intervent
kshvassoci
malign
diseas
conduct
cell
viabil
assay
detect
signific
chang
cell
number
two
day
treatment
cell
sinc
express
low
ratio
normal
pel
cell
suppress
might
result
immedi
effect
cell
growth
earlier
studi
show
ppmo
specif
suppress
protein
express
kshv
rta
lana
applic
rtaspecif
ppmo
cell
result
reduct
kshv
viral
dna
level
intracellular
cultur
supernat
sampl
blockag
express
result
slower
growth
cell
studi
show
anoth
product
target
inhibit
kshv
infect
result
indic
block
express
latent
earli
lytic
gene
effect
strategi
inhibit
kshv
infect
may
lead
benefici
effect
control
kshvassoci
malign
diseas
scid
mous
model
pel
repres
effect
vivo
approach
assess
efficaci
ppmo
inhibit
pel
engraft
ppmo
block
pel
develop
scid
mice
consist
effect
inhibit
express
growth
two
ppmo
less
effect
scid
mice
though
two
five
mice
neglig
engraft
cell
indic
dose
ppmo
suffici
extend
inhibitori
effect
cell
scid
mice
anoth
possibl
reason
express
might
dispens
pel
engraft
scid
mice
current
antiherpesviru
drug
target
late
lytic
phase
herpesviru
replic
report
cidofovir
foscarnet
effici
commerci
avail
compound
kshv
cidofovir
foscarnet
effect
express
latent
earli
lytic
gene
drug
inhibitor
viral
dna
polymeras
transcript
earli
lytic
gene
occur
dna
replic
kshv
earli
lytic
gene
play
import
role
kshv
replic
pathogenesi
result
indic
may
effect
target
antivir
therapi
addit
inhibit
earli
lytic
gene
may
posit
implic
manag
kshvinduc
lymphoma
develop
studi
investig
capac
ppmo
suppress
kshv
tumorigenesi
need
refer
web
version
pubm
central
supplementari
materi
antibodi
assess
protein
load
mocktreat
cell
also
includ
comparison
graphic
illustr
densitometri
analysi
digit
imag
shown
right
level
shown
rel
percentag
mocktreat
control
c
cell
detect
western
blot
cell
treat
figur
right
graphic
illustr
densitometri
analysi
digit
imag
inhibit
express
cell
graphic
illustr
densitometri
analysi
digit
imag
shown
right
e
doserespons
inhibit
express
cell
treatment
detect
western
blot
cell
induc
tpa
graphic
illustr
densitometri
analysi
digit
imag
shown
right
averag
ratio
cell
periton
lavag
ppmotreat
scid
mice
analyz
flow
cytometri
percentag
cell
among
total
cell
periton
lavag
mous
use
calcul
averag
ratio
group
sampl
collect
week
deliveri
b
sampl
collect
week
deliveri
dead
mice
count
calcul
averag
ratio
cell
group
error
bar
repres
variat
among
five
mice
group
signific
differ
group
denot
indic
p
surviv
curv
ppmotreat
scid
mice
engraft
cell
one
mous
mocktreat
group
fill
diamond
one
mous
group
cross
mice
group
fill
squar
die
week
five
mice
group
fill
triangl
one
mous
group
still
healthi
week
mice
euthan
week
due
poor
health
condit
observ
end
week
